SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim data from its RAD 101 Phase 2b imaging trial, sparking significant community discussion around the potential for a short squeeze and high price targets. The stock's impressive pre-market surge and subsequent volatility have traders weighing the potential for further gains against the risk of a pullback. A forthcoming webinar is adding to the anticipation, with many speculating on its impact on the stock's direction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, driven by sector-wide concerns about an AI bubble and delayed data center projects, despite a major Microsoft deal. Community sentiment is divided, with some calling the stock a "scam" and expecting further declines, while others view the dip as a buying opportunity, citing strong fundamentals and long-term growth potential. Discussions also revolve around potential market manipulation and the stock's correlation with Bitcoin's price movements.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a potential short squeeze, with community members discussing high trading volume and a tight float. Optimistic traders are setting high price targets, while others caution about volatility and potential pullbacks. The stock's connection to AI-powered robotics and recent contract news may also be contributing to the heightened interest.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other HK stocks that have seen explosive runs. Community members are highlighting the company's recent acquisitions and revenue, anticipating news that could catalyze a significant price movement. Some traders caution against FOMO due to the stock's volatility and low volume.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending as community members discuss the potential impact of autonomous driving tests and analyst upgrades. Bullish sentiment is fueled by the possibility of Tesla achieving new highs, while bears express concerns about valuation. Options activity and overall market conditions are also contributing to the conversation around the stock.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's stock is trending amid discussions around its AI strategy and potential partnerships, particularly after some analysts suggested it's lagging behind competitors. The community is debating whether Apple's lower AI spending is a strength or weakness, with some viewing it as a safe haven play. Additionally, there's speculation about Apple's next moves in response to increasing competition and evolving market dynamics.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending as investors digest news of a potential $19.5 billion write-down related to its EV strategy, with community discussions focusing on the implications of scaling back EV investments and shifting towards hybrids. Some view this pullback as a pragmatic move aligning with current market demand and improving profitability, while others question the company's leadership and long-term EV commitment. Broader conversations include the impact on Tesla and potential industry-wide EV write-downs.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending as investors anticipate a potential FDA approval for Narsoplimab by late December, with the community actively discussing the likelihood of approval and potential buyout scenarios. Recent price action and large put buys have sparked speculation about a possible news leak or market manipulation. Bullish investors express confidence in the drug's efficacy and Novo Nordisk's backing, viewing any price dips as buying opportunities.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a mix of AI sector excitement and volatility driven by broader market concerns and crypto price movements; the community is actively debating the stock's potential amidst discussions of data center demand and power dynamics, while some traders express frustration with the stock's trading pattern and perceived manipulation, and some suggest it is tied to Bitcoin's performance.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending following FDA Fast Track designation for its AlloNK cell therapy in refractory rheumatoid arthritis, sparking community discussion around the potential impact and future data releases. The community is also discussing the company's financial health and upcoming data in November and is debating potential price movements. The stock is seeing increased attention, with some analysts raising price targets, and the community speculates on both short-term gains and long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts.</li><li>Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.</li><li>Retail traders on Stocktwits turned extremely bullish on LABU as message volume surged.</li></ul>The biotech sector rallied sharply on Wednesday after Wall Street analysts said the latest round of U.S. Medicare drug-price cuts would have a smaller impact on pharmaceutical companies than initially feared, lifting the Direxion Daily S&amp;P Biotech Bull 3X Shares ETF (LABU) to its highest level in nearly 20 months.The&nbsp;<a href="https://stocktwits.com/symbol/LABU">LABU ETF</a> extended its rally on Wednesday, rising 3.7% to close at $165.5 and edging up 0.2% after hours, marking its fourth straight session of gains.<h2 class="st-heading-2">Bernstein Says Semaglutide Pricing Is ‘Final Cloud To Clear’</h2>Shares of major drugmakers jumped after the U.S. government published negotiated Medicare prices for 15 drugs late Tuesday, with cuts of up to 85% scheduled to begin in 2027.Novo Nordisk’s U.S.-listed shares rose&nbsp;nearly 4%, and Teva Pharmaceuticals gained over 5%, after their flagship therapies appeared on the pricing list. Novo’s semaglutide drugs, Ozempic and Wegovy, along with Teva’s Austedo, were included among the treatments subject to reductions.Bernstein analyst Christian Moore said the negotiated price for Novo’s semaglutide was “the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-shares-rise-us-medicare-price-cuts-come-largely-expected-2025-11-26/">reported</a>.<h2 class="st-heading-2">Goldman Sachs Says Austedo Cut Milder Than Expected</h2>Goldman Sachs analyst Matt Dellatorre noted that Austedo’s 38% price cut came in lower than the roughly 45% reduction modeled. He said the updated government price, which is a little over $700 lower per monthly supply versus one estimate of its net price, was below expectations and therefore less damaging for Teva.<h2 class="st-heading-2">Guggenheim Flags Deeper Than Expected Cuts For AbbVie</h2>Guggenheim analyst Vamil Divan said AbbVie’s cuts on Linzess and Vraylar, which come up to 75% and 44%, respectively, were deeper than anticipated.Two analysts said they are now watching how Medicare plans will manage access to the first batch of 10 drugs whose new negotiated prices take effect in January 2026, and what the Feb. 1 announcement of the next 15 drugs for 2028 will reveal.<h2 class="st-heading-2">Bernstein, William Blair, And Others Say Impact Already Priced In</h2>Bernstein analysts said five of the 15 targeted medicines will be generic by 2027, limiting exposure to deeper cuts. They added that lower prices could keep patients on branded therapies longer, potentially supporting volumes.William Blair analysts said the $274 monthly Medicare price for Novo’s semaglutide broadly tracks recent government agreements but added that insurance-coverage expansion remains uncertain. Analysts also said reductions had already been reflected in forecasts for Novo Nordisk, AstraZeneca and GSK.&nbsp;Earlier this month, Novo said it expected a low single-digit global sales impact if pricing were implemented this year, which analysts indicated translates to roughly DKK 6 billion.<h2 class="st-heading-2">Liquidity Wave Drives LABU Frenzy On Stocktwits</h2>On Stocktwits, retail sentiment for LABU was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/143;" src="https://news.stocktwits-cdn.com/labu_ss_png_d696fb5c91.webp" alt="labu ss.png" width="970" height="143"><figcaption>LABU sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user said, “This concentrated burst of purchasing power is pushing up prices.”<stembedurl>https://stocktwits.com/JesusHolbrook/message/637590765</stembedurl>Another user said the move looks close to a blow-off top, possibly around $165–$175, and warned that any pullback could echo the sharp drop seen after the Covid peak.<stembedurl>https://stocktwits.com/bottomfishtrader/message/637525624</stembedurl>The LABU ETF has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The LABU ETF has risen 22% so far in 2025. (Photo credit: Getty Images)

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Equity

Best-Performing Leveraged ETFs of October 

October's top ETF gainers included the likes of NVTX, AMUU, KORU, LABU and INTW. These ETFs soared as AI, crypto and reform optimism drove markets higher.

<ul class="summary-bullets"><li>The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.</li><li>In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025. &nbsp;</li></ul>The U.S. Food and Drug Administration on Friday said that it has approved Syndax Pharmaceuticals’ (SNDX) Revuforj for some relapsed or refractory acute myeloid leukemia (ACL) patients with particular mutations.The agency <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation">approved</a> the medicine for both adults and pediatric patients one year and older with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. &nbsp;<h2 class="st-heading-2">Implication For Patients, Syndax</h2>According to Syndax, mutations in the NPM1 gene are the most common genetic alteration observed in AML, occurring in approximately 30% of adults with the condition. Patients with the mutation have a poor prognosis, and there are currently no approved therapies that selectively target the underlying disease mechanism driving the cancer, it said.Revuforj was launched in the U.S. in November 2024 for the treatment of a specific type of leukemia called relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The new FDA approval expands the indication for the drug.In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 4% on Friday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNDX">SNDX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock is a good buy below $20.<stembedurl>https://stocktwits.com/dcrown/message/633624243</stembedurl>Another raised doubts about the possibility of a major rally.<stembedurl>https://stocktwits.com/Olena/message/633527864</stembedurl>SNDX stock is up by 15% this year but down by about 20% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/teladoc-stock-shoots-up-bofa-views-it-as-differentiated-asset-but-cautious-on-near-term-outlook/cLGJuuUR3ti">Teladoc Stock Shot Up 8% Today: BofA Views It As Differentiated Asset But Remains Cautious On Near-Term Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval 

The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.

Leveraged ETF Areas of Last Week That Are Up At least 15%

Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.

Current Price	$163.61
Prev Close	$164.81
Open	$166.23
Dividend Yield	N/A
50-Day Moving Average	$132.22
Beta	N/A
Avg. Volume	909,151.95
PE Ratio	N/A

52-Week High	$176.44
52-Week Low	$32.55
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

LABU
Direxion Daily S&P Biotech Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest LABU News

LABUDirexion Daily S&P Biotech Bull 3X Shares